Metropolis Healthcare Launches Centre of Genomics to Scale Precision Diagnostics in India

Metropolis has also deployed Illumina’s NovaSeq X Series for research purposes, significantly enhancing its sequencing throughput and accuracy.

Metropolis Healthcare has announced the launch of its Centre of Genomics, backed by CAP-accredited laboratories and high-throughput sequencing, signalling a strategic move to strengthen precision diagnostics and clinically actionable genomics in India.

The centre has been positioned to deliver clinically relevant genomic insights across the care continuum, with a focus on improving diagnostic accuracy, therapy selection, and long-term disease management through genomics.

The launch builds on Metropolis’s existing investments in advanced genomics, particularly in precision oncology, which have been anchored by its Global Reference Laboratory in Mumbai.

Following the integration of Core Diagnostics’ specialised genomics laboratory in the Delhi NCR region, the company has aligned these complementary facilities to operate as CAP-accredited national referral laboratories for genomics.

Together, these laboratories now form the operational backbone of the Centre of Genomics, supporting testing across oncology, reproductive health, neurology, transplant immunology, and rare genetic disorders.

As part of the Centre of Genomics’ technology upgrade, Metropolis has deployed Illumina’s NovaSeq™ X Series for research purposes, significantly enhancing its sequencing throughput and accuracy.

According to the company, the NovaSeq X Plus system can generate more than 20,000 whole genomes annually, more than double the capacity of earlier sequencing platforms. The system uses Illumina’s XLEAP-SBS chemistry, which is designed to support faster sequencing at scale while maintaining high data quality, enabling more comprehensive genomic analysis.

Beyond the newly added NovaSeq X Series, the Centre is supported by a multi-platform next-generation sequencing infrastructure already operational across Metropolis’ genomics hubs.

The company currently offers more than 220 validated genomic tests and has indicated plans to expand its portfolio to over 500 advanced genomic assays over the next two to three years. The expanded test menu is expected to cover a broader range of clinical use cases, from targeted panels to complex whole-genome and whole-exome analyses.

The Centre of Genomics also brings together multidisciplinary teams including molecular pathologists, genomic scientists, bioinformaticians, researchers, and certified genetic counsellors.

This integrated model is intended to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful reports for physicians and patients, supported by AI-enabled analytics and deeper digital integration.

Stay tuned for more such updates on Digital Health News